SecBot SecBot

RLMD

RELMADA THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001553643 Biotech & Drug Discovery
$3.61 −0.60 (−14.25%)
Nov 16 4:00 PM ET · prev $4.21
Market cap
$443.9M
Small cap
Median target
$11.00
+205% · range $9.00–12.00
1 year
−9.1%
from $3.97 · Nov 17
30 days
+14.2%
from $3.16
52-week range
$3.10–7.86
−54% from high · low Oct 16
Avg volume 20D
1.78M
Oct 22 spike 6.28M
Short interest
10.84M
≈10.2% of shares · −11.0%
Days to cover
6.4
at average volume
Insider net
+$1.7M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.7M at an average $4.18. No open-market sales. Price is 14% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 21 added (0 new), 8 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.162 → −$0.125 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −11.0% to 10.84M shares. 6.4 days to cover, ≈10.2% of shares.

  • TrendRANGE

    4% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPADD3,309,355$12.5M
Qube Research & Technologies LtdDOUBLED1,911,342$7.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,180,661$4.5M
Walleye Capital LLCADD1,015,489$3.8M
MARSHALL WACE, LLPTRIM603,357$2.3M
RENAISSANCE TECHNOLOGIES LLCDOUBLED503,192$1.9M
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED420,451$1.6M
UBS Group AGDOUBLED405,539$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +205%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jun 18, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$1.7M
bought · 2 insiders
$0
sold · 0 insiders
−13.6%
vs their $4.18 cost
DateInsiderTypeValue
Sep 10, 2026
Shenouda Maged
Chief Financial Officer
Sep 10, 2026
BUY$339.1K
Sep 10, 2026
TRAVERSA SERGIO
Chief Executive Officer
Sep 10, 2026
BUY$410.0K
Sep 9, 2026
Shenouda Maged
Chief Financial Officer
Sep 9, 2026
BUY$504.8K
Sep 9, 2026
TRAVERSA SERGIO
Chief Executive Officer
Sep 9, 2026
BUY$418.0K

Earnings setup

Estimates
−$0.13
EPS estimate, this quarter
+23%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.15–-$0.09+20.6%$0.00
Next Q-$0.14-$0.18–-$0.11+12.1%$0.00
Current FY-$0.41-$0.41–-$0.41-13.9%$0.00
Next FY-$0.41-$0.41–-$0.41+10.9%$0.00

Short side

FINRA· Oct 30, 2026
10,839,074
shares short
-11.0%
vs prior settlement
6.4
days to cover
≈10.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Other
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Re
Nov 12, 2026 SEC
Relmada reported Q3 2026 net loss of $13.9M ($0.12/share), wider than the $10.1M loss in Q3 2025, driven by increased…
8-K · Impact 4/10
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
3,309,355 shares ($12.5M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
1,911,342 shares ($7.2M)
Sep 10, 2026 Insider
Shenouda Maged bought 79,800 shares
Chief Financial Officer @ $4.25 ($339.1K)
Sep 10, 2026 Insider
TRAVERSA SERGIO bought 100,000 shares
Chief Executive Officer @ $4.10 ($410.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Press release
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM…
Nov 12, 2026
Earnings result
RLMD Q3 2026 Earnings: EPS $-0.12 (+18.9% vs est)
Nov 3, 2026
Earnings
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage…
Sep 1, 2026
Press release
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage…
Aug 6, 2026
Earnings date
RLMD Q2 2026 Earnings Scheduled, 2026-08-06

SecBot reports

8 filings · 3 press releases · 1 bullish · 2 bearish · 5 neutral
All RLMD filing & press-release reports (11)